Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.33 USD | +3.25% | +0.30% | -21.96% |
Sales 2024 * | 694M 57.83B | Sales 2025 * | 764M 63.73B | Capitalization | 1.22B 102B |
---|---|---|---|---|---|
Net income 2024 * | 60M 5B | Net income 2025 * | 91M 7.59B | EV / Sales 2024 * | 1.89 x |
Net Debt 2024 * | 83.94M 7B | Net cash position 2025 * | 119M 9.95B | EV / Sales 2025 * | 1.45 x |
P/E ratio 2024 * |
21.5
x | P/E ratio 2025 * |
13.5
x | Employees | 712 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.74% |
Latest transcript on Pacira BioSciences, Inc.
1 day | +3.25% | ||
1 week | +0.30% | ||
Current month | -9.89% | ||
1 month | -7.65% | ||
3 months | -17.85% | ||
6 months | -3.52% | ||
Current year | -21.96% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 56 | 02/01 |
Director of Finance/CFO | 63 | 01/11/01 | |
Jonathan Slonin
CTO | Chief Tech/Sci/R&D Officer | 49 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Pace
BRD | Director/Board Member | 76 | 01/08/01 |
Paul Hastings
CHM | Chairman | 64 | 02/11/02 |
Andreas Wicki
BRD | Director/Board Member | 64 | 01/06/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 27 M€ | -5.03% | - | |
0.18% | 45 M€ | +0.20% |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 26.33 | +3.25% | 304,606 |
25/24/25 | 25.5 | -1.54% | 305,838 |
24/24/24 | 25.9 | -3.39% | 359,410 |
23/24/23 | 26.81 | +2.72% | 497,169 |
22/24/22 | 26.1 | -0.57% | 375,229 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.96% | 1.22B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- PCRX Stock